미국의 복합 말초혈관 기기 시장 : 시장 규모, 점유율, 동향 분석(2025-2031년)

The U.S. complex peripheral vascular device market was valued at over $6.4 billion in 2024. The market is projected to grow to nearly $8.5 billion over the forecast period.

This report suite covers peripheral vascular stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy systems, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices, peripheral thrombus management devices, and peripheral intravascular ultrasound (IVUS) catheters.

While some devices have coronary applications, all sizing and forecasts in this edition address peripheral procedures only.

Quantitative coverage includes unit sales, average selling prices, market size, growth rates, procedure numbers, and company shares.

Qualitative coverage includes market drivers and limiters, mergers and acquisitions, technology and practice trends, and competitive positioning across hospitals, office based labs, and ambulatory settings that perform endovascular care.

Market Overview

Peripheral arterial and venous disease are major sources of morbidity in the United States.

Care pathways continue to shift from open surgery to endovascular treatment that allows shorter stays and faster recovery when clinically appropriate.

Within the arterial system, physicians rely on PTA balloons, DCBs, stents, atherectomy, IVUS, and lithotripsy to cross lesions, prepare the vessel, and maintain patency. In aortic and peripheral aneurysm care, stent grafts provide a minimally invasive alternative to open repair.

In venous disease, demand is rising for thrombectomy and embolization, venous stents, IVUS navigation, and protection from pulmonary embolism in selected cases. Growing awareness, better imaging, and more predictable tools are expanding the number of treatable patients and are improving outcomes.

Clinical programs also reflect practical constraints. Pricing pressure is most visible in office based labs where discounting and bundled offers are common.

Procurement choices depend on indication, setting, and evidence of durability, especially after concerns about paclitaxel safety reduced growth expectations for DCBs compared with pre-2019 trends.

The overall market remains diverse and innovation continues to add options, which supports steady value growth through the forecast period.

Market Drivers

Venous market development. Venous disease occurs at a rate roughly five times higher than arterial disease. Pulmonary embolism affects about 600,000 people in the United States each year and is often linked to deep vein thrombosis in the legs. DVT affects about 900,000 people annually, yet many patients are asymptomatic and sudden death can be the first sign in a meaningful share of cases. As education and screening improve, the number of patients treated for venous obstruction and thromboembolic disease will rise. IVUS already exceeds 50 percent penetration in deep venous procedures in some programs and is closely associated with treatment of iliac, iliofemoral, common femoral, and inferior vena cava lesions.

Growing public awareness. Outreach by medical institutions and public agencies has increased awareness of peripheral arterial and venous disease. Screening identifies more candidates for intervention before severe symptoms or limb-threatening ischemia develop. Stroke prevention programs highlight the role of carotid disease. These efforts move more patients into diagnostic and treatment pathways across arterial and venous categories.

Innovation. New options have expanded the toolkit since 2015. Intravascular lithotripsy and transcarotid artery revascularization (TCAR) add choices that can simplify difficult anatomy or reduce embolic risk. DCB indications continue to broaden in specific settings such as arteriovenous access, and below-the-knee DCB is expected to join the U.S. market. Thrombectomy platforms that reduce or eliminate thrombolytics shorten treatment time and reduce bleeding risk, including solutions that are cleared for pulmonary embolism. Stent graft indications continue to expand and covered stents, hydrophilic catheters, and guidewires command premium pricing where they reduce procedure time and complications.

Market Limiters

Paclitaxel safety concerns. A 2018 meta-analysis identified a late mortality signal in trials of paclitaxel-coated devices used for PAD. This prompted FDA scrutiny and a 2019 communication that supported continued use while calling for further study. The event triggered a sharp decline in DCB and drug-eluting stent volumes and a shift back to alternatives. Recovery is expected but long-term growth remains lower than before the re-evaluation.

Competition and pricing in OBLs. Office based labs purchase at prices that are already about 30 percent below hospital levels. Intense competition for OBL contracts and the use of bundled offers that include sheaths, guidewires, and catheters with core therapy devices drive average selling prices lower. Smaller firms without broad portfolios face pressure to discount, which can limit their ability to invest and may slow innovation if consolidation reduces market diversity.

Maturing femoral-popliteal segment. Years of focus on fem-pop disease have produced many treatment options and stable practices. As other indications develop and patient selection improves, growth in fem-pop interventions is expected to stabilize at a rate closer to overall procedural growth, rather than the rapid expansion seen earlier.

Market Coverage and Data Scope

Quantitative coverage. Market size, market shares, market forecasts, growth rates, units sold, average selling prices, and procedure numbers.

Qualitative coverage. Growth trends, market limiters, competitive analysis and SWOT for top competitors, mergers and acquisitions, company profiles and product portfolios, FDA clearances and recalls where applicable, disruptive technologies, and disease overviews that influence therapy selection.

Time frame. Base year 2024, forecasts 2025 to 2031, historical data 2021 to 2023.

Data sources. Primary interviews with industry leaders, government physician and procedure data, regulatory data, hospital and OBL inputs, import and export data, and the iData Research internal database.

Method note. Revenue is modeled from units multiplied by ASP and validated against installed base, procedure mix, setting shifts, and policy impacts.

Markets Covered and Segmentation

Peripheral Vascular Stent Market

Device type. Arterial stent and venous stent.

PTA Balloon Catheter Market

Device type. Standard, high-pressure, large, small, and specialty.

Unit analysis by application. Central venous or hemodialysis access, femoral-popliteal, iliac, infra-popliteal, renal, carotid, aorta, and others.

Drug-Coated Balloon Market

Indication. Superficial femoral artery, below the knee, and arteriovenous access.

Unit analysis by care setting. Hospital and office based lab.

Atherectomy Device Market

Device technology. Laser atherectomy device and mechanical atherectomy disposable.

Intravascular Lithotripsy Market

Care setting. Hospital and office based lab.

CTO Device Market

Device technology. Re-entry and re-canalization.

Surgical Graft Market

Indication. Lower limb, aorta repair, and extra-anatomical bypass.

Material. Polyester and PTFE.

Stent Graft Market

Device type. Abdominal aortic aneurysm, femoral or femoral access related applications, and thoracic aortic aneurysm.

Embolic Protection Device Market

Device type. Carotid and alternative.

Peripheral Thrombus Management Market

Device type. Traditional thrombectomy device, pharmacomechanical thrombectomy device, and catheter directed thrombolysis.

Indication. AV access, arterial, and venous.

Peripheral IVUS Market

Inferior Vena Cava Filter Market

Device type. IVC filter and IVC filter retrieval device.

Carotid Shunt

Transcarotid Artery Revascularization (TCAR) Market

Device type. Transcarotid bare-metal stent and TCAR neuroprotection system.

Diagnostic and Interventional Catheter Market

Device type. Diagnostic catheter and support catheter.

Diagnostic and Interventional Guidewire Market

Device type. Standard and hydrophilic.

Introducer Sheath Market

Device type. Standard and guiding.

Vascular Closure Device Market

Device type. Non-invasive and invasive.

Approach. Radial and femoral.

Transcatheter Embolization Market

Device type. Particle, coil, liquid, and plug.

Competitive Analysis

W. L. Gore led the total complex peripheral vascular device market in 2024 based on leadership in stent grafts and gains in covered stents following approval of the VBX iliac covered stent.

Medtronic ranked second with large revenue in stent grafts, DCBs, and atherectomy. The company led the DCB market and leveraged its portfolio across PTA, bare-metal stents, and atherectomy in hospitals and OBLs.

Boston Scientific ranked third following acquisitions that expanded its portfolio, including the BTG purchase. The company strengthened its venous portfolio with VICI venous stents while maintaining share with Wallstent and growing positions in oncology and deep vein thrombosis care.

Other participants compete across balloons, stents, atherectomy, thrombectomy, IVUS, lithotripsy, and closure.

Advantages come from portfolio breadth, performance, OBL pricing strategies, and support programs for vascular teams.

Technology and Practice Trends

IVUS integration in venous care. Deep venous programs use IVUS frequently to size and position venous stents and to evaluate obstructions.

Lithotripsy and vessel preparation. Calcium management using intravascular lithotripsy supports better expansion and reduces complications in difficult lesions.

Atherectomy and thrombus tools. Mechanical and laser systems are used to debulk plaque or remove clot where indicated, with growing interest in platforms that do not require thrombolytics.

Covered stents and stent grafts. Covered solutions gain share where they reduce restenosis, protect from embolization, or enable durable remodeling.

Procedure standardization. Programs create trays and protocols by indication and setting, which improves throughput and reduces variation.

Care Settings

Coverage includes hospitals, comprehensive vascular and stroke centers, community hospitals that perform elective endovascular procedures, office based labs that focus on peripheral interventions, and ambulatory settings that support specific cases.

Setting differences influence device selection, bundle adoption, service contracts, and achievable price corridors.

Geography

This edition covers the United States.

Why This Report

Where is the largest and fastest growing opportunity within the U.S. complex peripheral vascular device market and how do stents, balloons, DCBs, atherectomy, lithotripsy, CTO tools, stent grafts, thrombus management, IVUS, and closure each contribute to value through 2031.

How does the peripheral device market relate to the broader U.S. economy and to provider operations, including staffing, capital budgets, and the shift of procedures to office based labs.

What forces will shape the market going forward, including venous disease awareness, dialysis growth, calcium management, expanded stent graft indications, and the continued role of embolic protection in carotid pathways.

How should programs plan product selection for fem-pop, iliac, infra-popliteal, renal, carotid, and aortic indications, and what evidence supports the use of IVUS, covered stents, or vessel preparation in each setting.

What is the expected balance between hospital and OBL purchasing, and how will bundled pricing, inventory planning, and service agreements affect average selling prices and vendor selection.

How will paclitaxel concerns affect DCB adoption and revenue mix, and what alternatives are most likely to fill gaps in specific indications.

Where will venous stenting grow fastest, and how will May-Thurner and other obstruction patterns shape demand for venous stents and IVUS.

What is the outlook for thrombectomy in AV access, arterial, and venous indications, and how do devices that reduce thrombolytic use change case time, risk, and cost.

How can suppliers and providers build durable pathways, including standardized trays, staff training, and data tracking to support outcomes and economics.

Which risks could slow growth, including reimbursement pressure, ASP compression in OBLs, consolidation that reduces competition, and capacity limits for advanced endovascular skills.

The U.S. complex peripheral vascular device market report from iData Research answers these questions with segment and setting models, company share analysis, procedure and pricing detail, and coverage that links indication-specific choices to device demand.

Use it to size opportunities by category, plan product roadmaps, align OBL and hospital programs, and set targets for pricing, contracting, and inventory.

TABLE OF CONTENT

Table Of Contents

List Of Figures

List Of Charts

U.S. Complex Peripheral Vascular Device Market Overview

Competitive Analysis

Emerging Markets And Technologies

Market Developments

Market Trends

Procedure Segmentation

Procedure Codes Investigated

Market Segmentation

Key Analysis Updates

Version History

Research Methodology

• Step 1: Project Initiation & Team Selection
• Step 2: Prepare Data Systems And Perform Secondary Research
• Step 3: Preparation For Interviews & Questionnaire Design
• Step 4: Performing Primary Research
• Step 5: Research Analysis: Establishing Baseline Estimates
• Step 6: Market Forecast And Analysis
• Step 7: Identify Strategic Opportunities
• Step 8: Final Review And Market Release
• Step 9: Customer Feedback And Market Monitoring

Impact Of Global Tariffs

U.S. Complex Peripheral Vascular Device Market Overview

• 3.1 Introduction
  • 3.1.1 Atherosclerosis
  • 3.1.2 Peripheral Arterial Disease (Pad)
• 3.2 Market Overview & Trend Analysis
  • 3.2.1 Complex Peripheral Vascular Market Overview & Trend Analysis
  • 3.2.2 Standard Peripheral Vascular Market Overview & Trend Analysis
• 3.3 Drivers And Limiters
  • 3.3.1 Market Drivers
  • 3.3.2 Market Limiters
• 3.4 Competitive Market Share Analysis
• 3.5 Mergers And Acquisitions

Procedure Numbers

• 4.1 Introduction
• 4.2 Procedures
  • 4.2.1 Total Complex Peripheral Vascular Procedures
  • 4.2.2 Total Peripheral Vascular Procedures By Device Type, Indication, Intervention And Care Setting
    • 4.2.2.1 Above-The-Knee Procedures
    • 4.2.2.1.1 Above-The-Knee Stent Procedures
    • 4.2.2.1.2 Above-The-Knee Poba Procedures By Care Setting
    • 4.2.2.1.3 Above-The-Knee Dcb Procedures By Care Setting
    • 4.2.2.1.4 Peripheral Intravascular Lithotripsy Procedures
    • 4.2.2.1.5 Above-The-Knee Atherectomy Without Stent Procedures By Care Setting
    • 4.2.2.1.6 Above-The-Knee Atherectomy With Stent Procedures By Care Setting
    • 4.2.2.1.7 Surgical Graft Procedures
    • 4.2.2.2 Below-The-Knee Procedures
    • 4.2.2.2.1 Below-The-Knee Stent Procedures
    • 4.2.2.2.2 Below-The-Knee Poba Procedures By Care Setting
    • 4.2.2.2.3 Intravascular Lithotripsy Procedures
    • 4.2.2.2.4 Below-The-Knee Atherectomy Without Stent Procedures By Care Setting
    • 4.2.2.2.5 Below-The-Knee Atherectomy With Stent Procedures By Care Setting
    • 4.2.2.2.6 Surgical Graft Procedures
    • 4.2.2.3 Iliac Procedures
    • 4.2.2.3.1 Iliac Stent Procedures
    • 4.2.2.3.2 Iliac Poba Procedures By Care Setting
    • 4.2.2.4 Av Access Procedures
    • 4.2.2.4.1 Av Access Covered Stent Procedures By Care Setting
    • 4.2.2.4.2 Av Access Poba Procedures By Care Setting
    • 4.2.2.4.3 Av Access Dcb Procedures By Care Setting
    • 4.2.2.5 Renal Procedures
    • 4.2.2.6 Carotid Procedures
  • 4.2.3 Peripheral Vascular Stent Procedures
    • 4.2.3.1 Peripheral Arterial Stent Procedures
    • 4.2.3.1.1 Bare-Metal Stent Procedures
    • 4.2.3.1.2 Covered Stent Procedures
    • 4.2.3.1.3 Drug-Eluting Stent Procedures
    • 4.2.3.2 Peripheral Venous Stent Procedures
  • 4.2.4 Pta Balloon Catheter Procedures
  • 4.2.5 Drug-Coated Balloon Procedures
    • 4.2.5.1 Drug-Coated Balloon Procedures By Care Setting
    • 4.2.5.2 Drug-Coated Balloon Procedures By Indication
  • 4.2.6 Atherectomy Procedures
    • 4.2.6.1 Atherectomy Procedures By Device Type
    • 4.2.6.2 Atherectomy Procedures By Indication
    • 4.2.6.2.1 Fem-Popliteal Artery Atherectomy Procedures By Type
    • 4.2.6.2.2 Infra-Popliteal Artery Atherectomy Procedures By Type
    • 4.2.6.3 Atherectomy Procedures By Care Setting
  • 4.2.7 Intravascular Lithotripsy Procedures
    • 4.2.7.1.1 Intravascular Lithotripsy Procedures By Indication
  • 4.2.8 Cto Device Procedures
    • 4.2.8.1 Cto Device Procedures By Type
  • 4.2.9 Surgical Graft Procedures
    • 4.2.9.1 Surgical Graft Procedures By Graft Material
    • 4.2.9.2 Surgical Graft Procedures By Indication
    • 4.2.9.2.1 Lower Limb Surgical Graft Procedures By Anatomy
    • 4.2.9.2.2 Aorta Repair Surgical Graft Procedures By Anatomy
  • 4.2.10 Stent Graft Procedures
    • 4.2.10.1 Endovascular Stent Graft Procedures By Type
    • 4.2.10.2 Evar Procedures
    • 4.2.10.2.1 Evar Procedures By Anatomy
    • 4.2.10.2.2 Evar Procedures By Device Type
    • 4.2.10.2.3 Evar Procedures By Complexity
    • 4.2.10.2.4 Evar Procedures By Fenestration
    • 4.2.10.2.5 Evar Procedures By Anesthesia Type
    • 4.2.10.2.6 Evar Procedures By Gender
    • 4.2.10.3 Tevar Procedures
    • 4.2.10.3.1 Tevar Procedures By Indication
    • 4.2.10.3.2 Tevar Procedures By Anesthesia Type
    • 4.2.10.3.3 Tevar Procedures By Gender
  • 4.2.11 Embolic Protection Procedures
    • 4.2.11.1 Embolic Protection Procedures By Type
  • 4.2.12 Peripheral Thrombus Management Procedures
    • 4.2.12.1 Peripheral Thrombus Management Procedures By Procedure Type
    • 4.2.12.2 Peripheral Thrombus Management Procedures By Indication
  • 4.2.13 Peripheral Ivus Procedures
    • 4.2.13.1 Peripheral Ivus Procedures By Indication
    • 4.2.13.2 Peripheral Ivus Procedures By Care Setting

Peripheral Vascular Stent Market

• 5.1 Introduction
  • 5.1.1 Peripheral Arterial Stents
    • 5.1.1.1 Off-Label Use
    • 5.1.1.2 Covered Stents
    • 5.1.1.3 Drug-Eluting Stents
    • 5.1.1.4 Infra-Popliteal Stenting
    • 5.1.1.5 Stent Length
    • 5.1.1.6 General Information
  • 5.1.2 Venous Stents
• 5.2 Market Overview
• 5.3 Market Analysis And Forecast
  • 5.3.1 Peripheral Arterial Stent Market
    • 5.3.1.1 Total Bare-Metal Peripheral Arterial Stent Market
    • 5.3.1.1.1 Bare-Metal Peripheral Arterial Stent Market By Indication
    • 5.3.1.1.2 Bare-Metal Stent Market By Delivery Platform
    • 5.3.1.2 Total Covered Stent Market
    • 5.3.1.2.1 Iliac Covered Stent Market
    • 5.3.1.2.2 Fem-Popliteal Covered Stent Market
    • 5.3.1.2.3 Av Access Covered Stent Market
    • 5.3.1.3 Total Drug-Eluting Stent Market
    • 5.3.1.3.1 Sfa Drug-Eluting Stent Market
    • 5.3.1.3.2 Infra-Popliteal Drug-Eluting Stent Market
  • 5.3.2 Peripheral Venous Stent Market
• 5.4 Unit Analysis
  • 5.4.1 Units Sold By Stent Length
    • 5.4.1.1 Bare-Metal Carotid Stent Units
    • 5.4.1.2 Bare-Metal Renal Stent Units
    • 5.4.1.3 Bare-Metal Iliac Stent Units
    • 5.4.1.4 Bare-Metal Fem-Popliteal Stent Units
• 5.5 Drivers And Limiters
  • 5.5.1 Market Drivers
  • 5.5.2 Market Limiters
• 5.6 Competitive Market Share Analysis

Pta Balloon Catheter Market

• 6.1 Introduction
• 6.2 Market Overview
• 6.3 Market Analysis And Forecast
  • 6.3.1 Total Pta Balloon Catheter Market
  • 6.3.2 Total Standard Pta Balloon Catheter Market
    • 6.3.2.1 Hospital Standard Pta Balloon Catheter Market
    • 6.3.2.2 Office-Based Lab Standard Pta Balloon Catheter Market
  • 6.3.3 Total High-Pressure Pta Balloon Catheter Market
    • 6.3.3.1 Hospital High-Pressure Pta Balloon Catheter Market
    • 6.3.3.2 Office-Based Lab High-Pressure Pta Balloon Catheter Market
  • 6.3.4 Total Large Pta Balloon Catheter Market
    • 6.3.4.1 Hospital Large Pta Balloon Catheter Market
    • 6.3.4.2 Office-Based Lab Large Pta Balloon Catheter Market
  • 6.3.5 Total Small Pta Balloon Catheter Market
    • 6.3.5.1 Small Pta Balloon Catheter Market By Balloon Size
    • 6.3.5.1.1 0.014" Small Pta Balloon Catheter Market
    • 6.3.5.1.2 0.018" Small Pta Balloon Catheter Market
    • 6.3.5.2 Small Pta Balloon Catheter Market By Care Setting
    • 6.3.5.2.1 Hospital Small Pta Balloon Catheter Market
    • 6.3.5.2.2 Office-Based Lab Small Pta Balloon Catheter Market
  • 6.3.6 Total Specialty Pta Balloon Catheter Market
    • 6.3.6.1 Hospital Specialty Pta Balloon Catheter Market
    • 6.3.6.2 Office-Based Lab Specialty Pta Balloon Catheter Market
• 6.4 Unit Analysis
  • 6.4.1 Units Sold By Application
• 6.5 Drivers And Limiters
  • 6.5.1 Market Drivers
  • 6.5.2 Market Limiters
• 6.6 Competitive Market Share Analysis
  • 6.6.1 Standard Pta Balloon Catheter Market
  • 6.6.2 High-Pressure Pta Balloon Catheter Market
  • 6.6.3 Large Pta Balloon Catheter Market
  • 6.6.4 Small Pta Balloon Catheter Market
  • 6.6.5 Specialty Pta Balloon Catheter Market

Drug-Coated Balloon Market

• 7.1 Introduction
• 7.2 Market Overview
• 7.3 Market Analysis And Forecast
  • 7.3.1 Total Drug-Coated Balloon Market
    • 7.3.1.1 Sfa Drug-Coated Balloon Market
    • 7.3.1.2 Av Access Dcb Market
• 7.4 Unit Analysis
  • 7.4.1 Units Sold By Care Setting
• 7.5 Drivers And Limiters
  • 7.5.1 Market Drivers
  • 7.5.2 Market Limiters
• 7.6 Competitive Market Share Analysis
  • 7.6.1 Emerging Competitors

Atherectomy Device Market

• 8.1 Introduction
• 8.2 Market Overview
• 8.3 Market Analysis And Forecast
  • 8.3.1 Atherectomy Device Market By Technology
    • 8.3.1.1 Total Laser Atherectomy Device Market
    • 8.3.1.1.1 Laser Atherectomy Disposable Market
    • 8.3.1.1.2 Laser Atherectomy Console Market
    • 8.3.1.2 Mechanical Atherectomy Disposable Market
  • 8.3.2 Atherectomy Disposable Market By Care Setting
    • 8.3.2.1 Hospital Atherectomy Disposable Market
    • 8.3.2.2 Office-Based Lab Atherectomy Disposable Market
• 8.4 Drivers And Limiters
  • 8.4.1 Market Drivers
  • 8.4.2 Market Limiters
• 8.5 Competitive Market Share Analysis

Intravascular Lithotripsy Market

• 9.1 Introduction
• 9.2 Market Analysis And Forecast
  • 9.2.1 Intravascular Lithotripsy Market By Care Setting
    • 9.2.1.1 Hospital Intravascular Lithotripsy Market
    • 9.2.1.2 Office-Based Lab Intravascular Lithotripsy Market
• 9.3 Drivers And Limiters
  • 9.3.1 Market Drivers
  • 9.3.2 Market Limiters
• 9.4 Competitive Market Share Analysis

Cto Device Market

• 10.1 Introduction
• 10.2 Market Overview
• 10.3 Market Analysis And Forecast
  • 10.3.1 Total Cto Device Market
  • 10.3.2 Re-Entry Device Market
  • 10.3.3 Re-Canalization Device Market
• 10.4 Drivers And Limiters
  • 10.4.1 Market Drivers
  • 10.4.2 Market Limiters
• 10.5 Competitive Market Share Analysis

Surgical Graft Market

• 11.1 Introduction
• 11.2 Market Overview
  • 11.2.1 Surgical Graft Market Overview By Indication
  • 11.2.2 Surgical Graft Market Overview By Material
• 11.3 Market Analysis And Forecast
  • 11.3.1 Total Surgical Graft Market
  • 11.3.2 Surgical Graft Market By Indication
    • 11.3.2.1 Total Lower Limb Surgical Graft Market
    • 11.3.2.1.1 Above-The-Knee Surgical Graft Market
    • 11.3.2.1.2 Below-The-Knee Surgical Graft Market
    • 11.3.2.2 Total Aorta Repair Surgical Graft Market
    • 11.3.2.2.1 Abdominal Aortic Aneurysm Surgical Graft Market
    • 11.3.2.2.2 Thoracic Aortic Aneurysm Surgical Graft Market
    • 11.3.2.3 Extra-Anatomical Bypass Surgical Graft Market
  • 11.3.3 Surgical Graft Market By Material
    • 11.3.3.1 Polyester Surgical Graft Market
    • 11.3.3.2 Eptfe Surgical Graft Market
• 11.4 Drivers And Limiters
  • 11.4.1 Market Drivers
  • 11.4.2 Market Limiters
• 11.5 Competitive Market Share Analysis

Stent Graft Market

• 12.1 Introduction
• 12.2 Market Overview
• 12.3 Market Analysis And Forecast
  • 12.3.1 Total Stent Graft Market
  • 12.3.2 Total Aaa Stent Graft Market
    • 12.3.2.1 Bifurcated Main Body Graft Market
    • 12.3.2.2 Contralateral/Ipsilateral Iliac Leg/Limb Market
    • 12.3.2.3 Aorto-Uni-Iliac (Aui) Stent Graft Market
    • 12.3.2.4 Iliac Extension Market
    • 12.3.2.5 Aortic Extension Market
  • 12.3.3 Total Faa Stent Graft Market
    • 12.3.3.1 Fenestrated Distal Bifurcated Graft Market
    • 12.3.3.2 Fenestrated Proximal Body Graft Market
  • 12.3.4 Taa Stent Graft Market
• 12.4 Drivers And Limiters
  • 12.4.1 Market Drivers
  • 12.4.2 Market Limiters
• 12.5 Competitive Market Share Analysis

Embolic Protection Device Market

• 13.1 Introduction
  • 13.1.1 New Applications
  • 13.1.2 Protection Mechanism
    • 13.1.2.1 Filter Devices
    • 13.1.2.2 Balloon Occlusion Systems
    • 13.1.2.3 Flow Redirection
• 13.2 Market Overview
• 13.3 Market Analysis And Forecast
  • 13.3.1 Total Embolic Protection Device Market
  • 13.3.2 Carotid Epd Market
  • 13.3.3 Total Alternative Epd Market
    • 13.3.3.1 Renal Epd Market
    • 13.3.3.2 Lower Limb Epd Market
• 13.4 Drivers And Limiters
  • 13.4.1 Market Drivers
• 13.5 Competitive Market Share Analysis

Peripheral Thrombus Management Market

• 14.1 Introduction
  • 14.1.1 Av Access Thrombectomy Devices
  • 14.1.2 Other Peripheral Applications Of Thrombectomy Devices
• 14.2 Market Overview
  • 14.2.1 Peripheral Thrombus Management Market Overview By Device Type
  • 14.2.2 Peripheral Thrombus Management Market Overview By Indication
• 14.3 Market Analysis And Forecast
  • 14.3.1 Total Peripheral Thrombus Management Market
  • 14.3.2 Peripheral Thrombus Management Market By Device Type
    • 14.3.2.1 Traditional Thrombectomy Market
    • 14.3.2.2 Pharmacomechanical Thrombectomy Market
    • 14.3.2.3 Catheter Directed Thrombolysis Market
  • 14.3.3 Peripheral Thrombus Management Market By Indication
    • 14.3.3.1 Av Access Thrombectomy Device Market
    • 14.3.3.2 Arterial Thrombectomy Device Market
    • 14.3.3.3 Venous Thrombectomy Device Market
• 14.4 Drivers And Limiters
  • 14.4.1 Market Drivers
  • 14.4.2 Market Limiters
• 14.5 Competitive Market Share Analysis

Peripheral Ivus Catheter Market

• 15.1 Introduction
• 15.2 Market Analysis And Forecast
• 15.3 Drivers And Limiters
  • 15.3.1 Market Drivers
  • 15.3.2 Market Limiters
• 15.4 Competitive Market Share Analysis

Abbreviations